Literature DB >> 26152321

Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe.

James Stone1, Vasileia Kotoula2, Craige Dietrich2, Sara De Simoni2, John H Krystal3, Mitul A Mehta2.   

Abstract

Ketamine produces effects in healthy humans that resemble the positive, negative and cognitive symptoms of schizophrenia. We investigated the effect of ketamine administration on brain activity as indexed by blood-oxygen-level-dependent (BOLD) signal change response, and its relationship to ketamine-induced subjective changes, including perceptual distortion. Thirteen healthy participants volunteered for the study. All underwent a 15-min functional MRI acquisition with a ketamine infusion commencing after 5 min (approx 0.26 mg/kg over 20s followed by an infusion of approx. 0.42 mg/kg/h). Following the scan, participants self-rated ketamine-induced effects using the Psychotomimetic States Inventory. Ketamine led to widespread cortical and subcortical increases in BOLD response (FWE-corrected p < 0.01). Self-rated perceptual distortions and delusional thoughts correlated with increased BOLD response in the paracentral lobule (FWE-corrected p < 0.01). The findings suggest that BOLD increases in parietal cortices reflect ketamine effects on circuits that contribute to its capacity to produce perceptual alterations and delusional interpretations.
© The Author(s) 2015.

Entities:  

Keywords:  BOLD; Ketamine; fMRI; psychosis

Mesh:

Substances:

Year:  2015        PMID: 26152321     DOI: 10.1177/0269881115592337

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  8 in total

1.  The P1 visual-evoked potential, red light, and transdiagnostic psychiatric symptoms.

Authors:  Jeffrey S Bedwell; Christopher C Spencer; Chi C Chan; Pamela D Butler; Pejman Sehatpour; Joseph Schmidt
Journal:  Brain Res       Date:  2018-03-03       Impact factor: 3.252

2.  Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.

Authors:  Mitul A Mehta; Anne Schmechtig; Vasileia Kotoula; Juliet McColm; Kimberley Jackson; Claire Brittain; Sitra Tauscher-Wisniewski; Bruce J Kinon; Paul D Morrison; Thomas Pollak; Timothy Mant; Steven C R Williams; Adam J Schwarz
Journal:  Psychopharmacology (Berl)       Date:  2018-03-21       Impact factor: 4.530

Review 3.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

4.  Effects of ketamine on brain function during response inhibition.

Authors:  M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2018-10-24       Impact factor: 4.530

5.  Acute effects of ketamine on the pregenual anterior cingulate: linking spontaneous activation, functional connectivity, and glutamate metabolism.

Authors:  Matti Gärtner; Anne Weigand; Milan Scheidegger; Mick Lehmann; Patrik O Wyss; Andreas Wunder; Anke Henning; Simone Grimm
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-12       Impact factor: 5.760

6.  Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?

Authors:  Jing J Wong; Owen O'Daly; Mitul A Mehta; Allan H Young; James M Stone
Journal:  PeerJ       Date:  2016-02-16       Impact factor: 2.984

7.  Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum.

Authors:  D R Roalf; R P R Nanga; P E Rupert; H Hariharan; M Quarmley; M E Calkins; E Dress; K Prabhakaran; M A Elliott; P J Moberg; R C Gur; R E Gur; R Reddy; B I Turetsky
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

Review 8.  Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.

Authors:  Moritz Haaf; Gregor Leicht; Stjepan Curic; Christoph Mulert
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.